$0.51
1.64% yesterday
Nasdaq, May 20, 10:03 pm CET
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Vaxart, Inc. Stock price

$0.51
+0.19 59.70% 1M
-0.10 16.42% 6M
-0.15 23.27% YTD
-0.39 43.35% 1Y
-3.21 86.34% 3Y
-2.68 84.08% 5Y
-24.79 97.99% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.01 1.64%
ISIN
US92243A2006
Symbol
VXRT
Sector
Industry

Key metrics

Market capitalization $115.94m
Enterprise Value $94.56m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.99
P/S ratio (TTM) P/S ratio 2.45
P/B ratio (TTM) P/B ratio 2.54
Revenue growth (TTM) Revenue growth 433.43%
Revenue (TTM) Revenue $47.40m
EBIT (operating result TTM) EBIT $-57.16m
Free Cash Flow (TTM) Free Cash Flow $-33.73m
Cash position $41.94m
EPS (TTM) EPS $-0.27
P/E forward negative
P/S forward 4.80
EV/Sales forward 3.92
Short interest 5.33%
Show more

Is Vaxart, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Vaxart, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Vaxart, Inc. forecast:

Buy
100%

Financial data from Vaxart, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
47 47
433% 433%
100%
- Direct Costs 4.40 4.40
5% 5%
9%
43 43
909% 909%
91%
- Selling and Administrative Expenses 9.81 9.81
30% 30%
21%
- Research and Development Expense 86 86
27% 27%
181%
-53 -53
32% 32%
-111%
- Depreciation and Amortization 4.40 4.40
5% 5%
9%
EBIT (Operating Income) EBIT -57 -57
30% 30%
-121%
Net Profit -58 -58
29% 29%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about Vaxart, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaxart, Inc. Stock News

Neutral
GlobeNewsWire
about 7 hours ago
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company's new Chief Financial Officer, Jeroen Grasman, effective May 19, 2025.
Neutral
GlobeNewsWire
5 days ago
Company Urges Stockholders to Vote ‘FOR' Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has filed a supplement to its proxy statement for its Annual Meeting.
Neutral
GlobeNewsWire
6 days ago
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS), to initiate dosing in the 10,000-participant portion of...
More Vaxart, Inc. News

Company Profile

Biota Holdings Pty Ltd. operates as an anti infective drug development firm. The company was founded on October 2, 1985 and is headquartered in Notting Hil, Australia.

Head office United States
CEO Steven Lo
Employees 115
Founded 2004
Website www.vaxart.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today